1. Scrip
  2. >>Business
  3. >>Strategy

Best Practices For Offering Value To Potential Partners – Highlights From LSX

 
• By Joseph Haas

At the 2024 LSX USA conference, panelists provided advice on how to approach companies in dealmaking and to make their value proposition fit with what the company is looking for.

Biz advice
Speakers at LSX USA 2024 offered best practices for dealmaking • Source: Shutterstock

With the flow of initial public offerings frustratingly sluggish and a tight financing environment, biopharma companies are looking for advice on other ways to bring in funding capital or explore business development options. In challenging times, experts agree it can be good to fall back on best practices.

Key Takeaways

  • Panelists at the recent LSX USA meeting offered advice to biotechs on how to approach partnering with deep-pocketed firms.

  • Suggestions included making enduring relationships...

At the LSX World Congress USA, held 11-12 September in Boston, speakers from biopharma and other life sciences firms were asked to share their best ideas for how to succeed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

More from Business